Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Universidad Autonoma, Madrid, Spain.
Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Universidad Autonoma, Madrid, Spain.
Clin Genet. 2020 Jun;97(6):857-868. doi: 10.1111/cge.13738. Epub 2020 Mar 25.
Autosomal dominant polycystic kidney disease (ADPKD) is a heterogeneous inherited disease characterized by renal and extrarenal manifestations with progressive fluid-filled cyst development leading to end-stage renal disease. The rate of disease progression in ADPKD exhibits high inter- and intrafamilial variability suggesting involvement of modifier genes and/or environmental factors. Renal hypouricemia (RHUC) is an inherited disorder characterized by impaired tubular uric acid transport with severe complications, such as acute kidney injury and chronic kidney disease (CKD). However, the two disorders have distinct and well-delineated genetic, biochemical, and clinical findings. Only a few cases of coexistence of ADPKD and RHUC (type 1) in a single individual have been reported. We report a family with two members: an ADPKD 24-year-old female which presented bilateral renal cysts in utero and hypouricemia since age 5, and her mother with isolated hypouricemia. Next-generation sequencing identified two mutations in two genes PKD1 and SLC2A9 in this patient and one isolated SLC2A9 mutation in her mother, showing RHUC type 2, associated to CKD. The coexistence of these two disorders provides evidence of SLC2A9 variant could act as a modifier change, with synergistic actions, that could promote cystogenesis and rapid ADPKD progression. This is the first case of coexistence of PKD1 and SLC2A9 mutations treated with tolvaptan.
常染色体显性多囊肾病(ADPKD)是一种异质性遗传性疾病,其特征为肾和肾外表现,伴有进行性充满液体的囊肿发展,导致终末期肾病。ADPKD 的疾病进展速度在个体间和家族内表现出高度的变异性,提示存在修饰基因和/或环境因素的参与。肾脏低尿酸血症(RHUC)是一种遗传性疾病,其特征为肾小管尿酸转运受损,伴有严重并发症,如急性肾损伤和慢性肾脏病(CKD)。然而,这两种疾病具有明显不同的遗传、生化和临床特征。仅有少数报道称单个个体同时存在 ADPKD 和 RHUC(1 型)。我们报告了一个有两名成员的家族:一名 24 岁的 ADPKD 女性,在子宫内就出现双侧肾囊肿,并且从 5 岁起就出现低尿酸血症;其母亲则表现为孤立性低尿酸血症。下一代测序在该患者中鉴定出两个基因 PKD1 和 SLC2A9 中的两个突变,以及其母亲中一个孤立的 SLC2A9 突变,表现为 2 型 RHUC,与 CKD 相关。这两种疾病的共存提供了证据表明 SLC2A9 变体可能作为修饰变化,具有协同作用,从而促进囊肿形成和 ADPKD 的快速进展。这是首例同时存在 PKD1 和 SLC2A9 突变的病例,并用托伐普坦治疗。